## **ORIGINAL INVESTIGATIONS**

# Femoral and Carotid Subclinical Atherosclerosis Association With Risk Factors and Coronary Calcium



## Martín Laclaustra, MD, PHD, MPH,<sup>a,b,c</sup> José A. Casasnovas, MD, PHD,<sup>d</sup> Antonio Fernández-Ortiz, MD, PHD,<sup>a,e</sup> Valentin Fuster, MD, PHD,<sup>a,f</sup> Monserrat León-Latre, MD,<sup>d</sup> Luis J. Jiménez-Borreguero, MD, PHD,<sup>a,g</sup> Miguel Pocovi, PHD,<sup>d</sup> Yamilee Hurtado-Roca, MD,<sup>a</sup> José M. Ordovas, PHD,<sup>a,h</sup> Estibaliz Jarauta, MD,<sup>d,i</sup> Eliseo Guallar, MD, PHD,<sup>j</sup> Borja Ibañez, MD, PHD,<sup>a,k</sup> Fernando Civeira, MD, PHD<sup>d,i</sup>

## ABSTRACT

The AWHS Study

**BACKGROUND** Early subclinical atherosclerosis has been mainly researched in carotid arteries. The potential value of femoral arteries for improving the predictive capacity of traditional risk factors is an understudied area.

**OBJECTIVES** This study sought to evaluate the association of subclinical carotid and femoral plaques with risk factors and coronary artery calcium score (CACS) in middle-aged men.

**METHODS** Participants (n = 1,423) of the AWHS (Aragon Workers' Health Study), a study designed to assess cardiovascular risk and subclinical atherosclerosis in a cohort of middle-aged men (40 to 59 years of age), underwent carotid and femoral ultrasound plus noncontrast coronary computed tomography. Subclinical atherosclerosis was defined as the presence of any plaque in carotid or femoral arteries and/or CACS  $\geq$ 1. Logistic regression models were used to estimate the prevalence of atherosclerosis adjusted for risk factors and age, to evaluate the association of atherosclerosis with risk factors, and to calculate areas under the receiver-operating characteristic curves for the presence of positive CACS.

**RESULTS** Subclinical atherosclerosis was found in 72% of participants. Plaques were most common in femoral arteries (54%), followed by coronary calcification (38%) and carotid plaques (34%). Association of atherosclerosis with risk factors was stronger in femoral arteries than carotid or coronary arteries. The area under the receiver-operating characteristic curve for prediction of positive CACS increased from 0.665 when considering only risk factors (dyslipidemia, current smoking, hypertension, diabetes, and age) to 0.719 when adding femoral and carotid plaques (p < 0.001). In this model, the femoral odds ratio (2.58) exceeded the carotid odds ratio (1.80) for prediction of positive CACS.

**CONCLUSIONS** Subclinical atherosclerosis was highly prevalent in this middle-aged male cohort. Association with risk factors and positive CACS was stronger in femoral than carotid arteries. Screening for femoral plaques may be an appealing strategy for improving cardiovascular risk scales and predicting coronary disease. (J Am Coll Cardiol 2016;67:1263-74) © 2016 by the American College of Cardiology Foundation.

Listen to this manuscript's audio summary by *JACC* Editor-in-Chief Dr. Valentin Fuster.



From the <sup>a</sup>Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; <sup>b</sup>Centro de Investigación Biomédica en Red - Epidemiología y Salud Pública (CIBERESP), Department of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain; <sup>c</sup>Department of Epidemiology, St. Louis University, St. Louis, Missouri; <sup>d</sup>Instituto Aragonés de Ciencias de Salud, IIS Aragón, Zaragoza, Spain; <sup>e</sup>Hospital Clínico San Carlos, Universidad Complutense, Madrid, Spain; <sup>f</sup>Mount Sinai School of Medicine, New York, New York; <sup>g</sup>Hospital Universitario La Princesa, Madrid, Spain; <sup>h</sup>U.S. Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts; <sup>i</sup>Hospital Universitario Miguel Servet, IIS Aragón, Zaragoza, Spain; <sup>i</sup>Departments of Epidemiology and Medicine, and Welch Center

#### ABBREVIATIONS AND ACRONYMS

ASCVD = atherosclerotic cardiovascular disease

CACS = coronary artery calcification score

- CT = computed tomography
- CVD = cardiovascular disease

HDL = high-density lipoprotein

**ROC** = receiver-operating characteristic

therosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality and disability in most countries (1). Approximately 30% of first acute events are fatal, and survivors often experience sequelae and a shortened life expectancy (2,3). Primary prevention is thus the best approach to fighting this pandemic disease. Current algorithms for risk detection, which combine behavioral, clinical, and biochemical markers, are of limited accuracy, and better risk stratification methods are defi-

## nitely needed (4,5).

#### SEE PAGE 1275

Used in combination with traditional risk factors, data on subclinical atherosclerosis can provide additional information about the risk of myocardial infarction, stroke, and cardiovascular disease (CVD) mortality (6-8). Carotid wall intima-media thickness estimated from ultrasonographic images has been proposed as a surrogate measure of subclinical atherosclerosis (9). Whereas some prospective studies have shown that intima-media thickness adds predictive capacity to traditional risk prediction models (10), others have not been able to confirm this (7,8,11), and consequently, the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guideline for CVD risk prediction no longer recommends its measurement (5). A higher predictive value has been attributed to the presence of carotid plaques, which added a significant net reclassification index of 7.3% in the Framingham Offspring Study cohort (6) and up to 17.7% in subjects with intermediate CVD risk (clinical net reclassification index) in the ARIC (Atherosclerosis Risk In Communities) study (10). In this study, considering plaques together with intima-media thickness further boosted the reclassification index to 21.7%. Moreover, the association of plaque with events has been confirmed in a meta-analysis of 11 cohort studies including 54,336 subjects (12).

The potential value of studying the presence of atherosclerotic plaques in other vascular territories, such as the femoral arteries, for further improving the predictive capacity of traditional risk factors is an understudied area. In a post-mortem study in the Netherlands, the femoral artery was the artery most frequently affected by atherosclerosis among 5 peripheral vascular sites, including the common carotid artery (13). Moreover, recent data from the PESA (Progression of Early Subclinical Atherosclerosis) study have shown a higher prevalence of femoral compared with carotid plaques in an asymptomatic cohort composed of middle-aged men and women (14). With this background, we hypothesize that early femoral plaques would be more closely associated with traditional risk factors than carotid plaques and, furthermore, that calcification of coronary arteries assessed by computed tomography (CT) would be more associated with femoral than with carotid plaques. The analyses to investigate these hypotheses were conducted on data from the AWHS (Aragon Workers' Health Study), a prospective study designed to identify risk factors for the development of preclinical and clinical atherosclerosis (15).

### METHODS

**STUDY SAMPLE**. Beginning in February 2009, factory workers at the General Motors automobile assembly plant in Figueruelas (Zaragoza, Spain) were invited to participate in the AWHS, a longitudinal cohort study that collected data during workers' programmed annual health examinations (15). After obtaining written informed consent, the research team gathered the clinical examination, collected blood and urine samples, and conducted questionnaires on cardiovascular and lifestyle risk factors. In addition, starting in 2011, all participants between 40 and 59 years of age were invited to undergo a noninvasive imaging exploration of subclinical atherosclerosis. Imaging included ultrasound measurements of the carotid and femoral arteries and CT to calculate the

Manuscript received September 13, 2015; revised manuscript received December 8, 2015, accepted December 27, 2015.

for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; and the <sup>k</sup>Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain. The AWHS (Aragon Workers' Health Study) is funded by the Instituto Aragonés de Ciencias de la Salud (I+CS) and the Spanish National Center for Cardiovascular Diseases (CNIC). Dr. Laclaustra was supported in part by grants FIS CP08/0012, Pl10/00021, and Pl14/00009 from the Instituto de Salud Carlos III, which includes FEDER funding. Dr. León-Latre was supported by FIS Pl12/01434. Dr. Pocovi was supported by FIS Pl12/01703. Dr. Hurtado-Roca was supported by FINCyT Science and Technology Program Scholarship N° 088-FINCyT-BDE-2014 from agreement 1663/0C-PE, between the Republic of Peru and the Inter-American Development Bank. Dr. Civeira was supported by FIS Pl12/01087 and RETIC RIC RD12/0042/0055; has received personal fees from Sanofi, Lilly, Synageva, Pfizer, and Amgen; and has received grants and personal fees from Merck. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Tasneem Z. Naqvi, MD, served as Guest Editor for this paper.

coronary artery calcium score (CACS). A total of 2,121 participants were recruited into the AWHS imaging study between January 2011 and December 2013 (2,013 men and 108 women, all Caucasians) and 1,564 completed the imaging exams in all targeted territories. Due to under-representation of the female sex in this cohort (only 80 women), women were excluded from the analysis, together with 61 male participants with incomplete cardiovascular profile data, rendering a final sample size of 1,423 male participants. The Aragon regional government's Ethics Committee for Clinical Research approved the study.

SUBCLINICAL ATHEROSCLEROSIS IMAGING. The presence of plaques in both carotid and femoral arteries was determined using the Philips IU22 ultrasound system (Philips Healthcare, Bothell, Washington). Ultrasound images were acquired with linear high-frequency 2-dimensional probes (Philips Transducer L9-3, Philips Healthcare), using the Bioimage Study protocol for the carotid arteries (16) and a specifically designed protocol for the femoral arteries (17) (Online Appendix). Plaque was defined as a focal structure protruding  $\geq 0.5$  mm into the lumen or reaching a thickness  $\geq$  50% of the surrounding intima, and all measurements were analyzed using electrocardiogram (ECG)-gated frames corresponding to end-diastole (R-wave) (16). Examination of the carotid territory included the terminal portion (10 mm) of the common carotid, the bulb, and the initial portion (10 mm) of the internal and external carotid arteries. The 20-mm segment of the common femoral artery, proximal to the bifurcation of the deep femoral artery, was considered in the search for femoral plaques. In all cases, plaques were recorded in both longitudinal and transverse planes to account for circumferential asymmetry.

CACS was obtained with a multidetector-row CT scanner (Mx 8000 IDT 16, Philips Medical Systems, Best, the Netherlands) using a low-dose, prospectively ECG-triggered, high-pitch spiral acquisition protocol. During a single breath hold, images were acquired from the tracheal bifurcation to below the base of the heart. Scan parameters were  $8 \times 3$  mm collimation, 220-mm field of view, 120 kVp, 55 mA, and 3-mm section thickness. Coronary calcium was quantified with calcium scoring software (Workspace CT viewer, Philips Medical Systems) that follows the Agatston method (18). The presence of coronary calcium was defined as any calcium score  $\geq$ 1 and was considered to identify atherosclerotic disease of the coronary wall.

A positive finding for subclinical atherosclerosis was defined as the detection of at least 1 plaque in any of the segments studied with vascular ultrasound or a CACS  $\geq$ 1 for coronary arteries. A variable termed "any atherosclerosis" was defined as positive if any of the 5 territories (coronary, both carotid, and both femoral arteries) was positive. A territory count was considered to also convey information about the extent of atherosclerosis, and participants were classified as disease-free (0 vascular sites affected) or as having focal (1 site), intermediate (2 to 3 sites), or generalized atherosclerosis (4 to 5 sites).

CLINICAL CHARACTERISTICS AND LABORATORY DATA.

Clinical and laboratory data were obtained during the annual medical examination. All study procedures were described in standard operating procedures. The study protocols conform to the ISO9001-2008 quality standard. Clinical data included medical history, current medication, anthropometry, blood pressure, and heart rate. Blood pressure was obtained as the mean of 3 consecutive measurements with an OMRON M10-IT automatic oscillometric sphygmomanometer (OMRON Healthcare Co. Ltd., Kyoto, Japan), with the participant resting in a seated position for 5 min between readings. Arterial hypertension was defined as having systolic blood pressure ≥140 mm Hg, diastolic blood pressure  $\geq$ 90 mm Hg, or self-reported use of antihypertensive medication (19). Blood and urine specimens were collected after overnight (>8 h) fasting and were processed for laboratory analyses the same day. Fasting serum glucose, triglycerides, total cholesterol, and high-density lipoprotein (HDL) cholesterol were measured by spectrophotometry (Chemical Analyzer ILAB 650, Instrumentation Laboratory Bedford, Massachusetts). SpA, Low-density lipoprotein was calculated. Whole blood glycosylated hemoglobin measured was hv reverse-phase cation exchange chromatography and quantified by double wavelength colorimetry (ADAMS A1c HA-810 Analyzer, Arkray Factory, Minneapolis, Minnesota). Dyslipidemia was defined as having total cholesterol ≥240 mg/dl, low-density lipoprotein cholesterol  $\geq$ 160 mg/dl, HDL cholesterol <40 mg/dl, or self-reported use of lipid-lowering drugs (20). Diabetes was defined as fasting plasma glucose ≥126 mg/dl or self-reported treatment with hypoglycemic medication (19). Current smoking was defined as smoking in the present or having smoked in the last year. Being a former smoker was defined as a subject having smoked at least 50 cigarettes in his lifetime, but not having smoked in the last year. A variable was created counting how many of the following 4 risk factors were present: hypertension, dyslipidemia, diabetes, and current smoking. In addition, the estimation of 10-year ASCVD risk was calculated using the Pooled Cohort Equations for white males, which are on

		MARCH	22,	2016
ddition	a logistic model	includ	lina	- 11

Presence of Any Subclinical Atherosclerosis					
	Total (N = 1,423)	No Atherosclerosis (n = 403)	Atherosclerosis in Any Territory (n = 1,020)	p Value (None vs. Any)	
Baseline characteristics					
Age, yrs	$51.0\pm3.7$	$\textbf{49.6} \pm \textbf{4.1}$	$51.6\pm3.4$	< 0.001	
BMI, kg/m <sup>2</sup>	$\textbf{27.6} \pm \textbf{3.3}$	$\textbf{27.1} \pm \textbf{3.2}$	$\textbf{27.9} \pm \textbf{3.3}$	< 0.001	
Systolic blood pressure, mm Hg	$126.2 \pm 13.9$	$\textbf{123.3} \pm \textbf{12.4}$	$127.4 \pm 14.3$	<0.001	
Diastolic blood pressure, mm Hg	$\textbf{83.2} \pm \textbf{9.2}$	$\textbf{81.8} \pm \textbf{8.7}$	$\textbf{83.7} \pm \textbf{9.3}$	<0.001	
Total cholesterol, mg/dl	$\textbf{223.1} \pm \textbf{36.2}$	$\textbf{218.5} \pm \textbf{36.1}$	$\textbf{224.9} \pm \textbf{36.1}$	0.002	
LDL-C, mg/dl	$140.5\pm31.6$	$\textbf{136.7} \pm \textbf{30.9}$	$142.1\pm31.7$	0.004	
HDL-C, mg/dl	$\textbf{52.8} \pm \textbf{11.3}$	$\textbf{55.3} \pm \textbf{11.8}$	$51.8\pm10.9$	< 0.001	
Triglycerides, mg/dl	$\textbf{153.0} \pm \textbf{96.0}$	$\textbf{136.2} \pm \textbf{89.5}$	$\textbf{159.6} \pm \textbf{97.7}$	< 0.001	
Fasting glucose, mg/dl	$\textbf{98.1} \pm \textbf{16.6}$	$\textbf{97.2} \pm \textbf{17.3}$	$\textbf{98.5} \pm \textbf{16.3}$	0.196	
HbA <sub>1c</sub> , %	$\textbf{5.5}\pm\textbf{0.5}$	$\textbf{5.4} \pm \textbf{0.5}$	$5.6\pm0.5$	< 0.001	
Lipid-lowering therapy	14.8 (210)	9.7 (39)	16.8 (171)	0.001	
Antihypertensive therapy	20.3 (289)	11.9 (48)	23.6 (241)	< 0.001	
Antidiabetic therapy	3.3 (47)	1.7 (7)	3.9 (40)	0.056	
Never smoker	31.8 (452)	45.9 (185)	26.2 (267)	< 0.001	
Former smoker	35.2 (501)	35.2 (142)	35.2 (359)	1.000	
CV risk factors					
Dyslipidemia	50.9 (724)	40.2 (162)	55.1 (562)	< 0.001	
Total cholesterol ≥240 mg/dl	30.4 (432)	25.3 (102)	32.4 (330)	0.011	
LDL-C ≥160 mg/dl	25.4 (355)	21.0 (83)	27.2 (272)	0.019	
HDL-C <40 mg/dl	9.1 (129)	5.5 (22)	10.5 (107)	0.004	
Hypertension	38.7 (550)	26.1 (105)	43.6 (445)	< 0.001	
Current smoking	33.0 (470)	18.9 (76)	38.6 (394)	< 0.001	
Diabetes	5.3 (76)	3.0 (12)	6.3 (64)	0.018	
Number of CV risk factors					
0	20.7 (294)	34.2 (138)	15.3 (156)	<0.001	
1	41.4 (589)	45.9 (185)	39.6 (404)	0.035	
2	28.0 (399)	17.4 (70)	32.3 (329)	< 0.001	
>2	9.9 (141)	2.5 (10)	12.8 (131)	< 0.001	

TABLE 1 Baseline Characteristics of the Total Study Population and According to the

Values are mean  $\pm$  SD or % (n).

 $BMI = body mass index; \mbox{ CV} = cardiovascular; \mbox{ HbA}_{1c} = glycosylated hemoglobin; \mbox{ HDL-C} = high-density lipoprotein cholesterol. \mbox{ LDL-C} = low-density lipoprotein cholesterol. \label{eq:body}$ 

the basis of age, total cholesterol, HDL cholesterol, treated or untreated systolic blood pressure, diabetes, and smoking status (5). ASCVD risk was classified as low (<5%), moderate (5% to 7.5%), or high ( $\geq$ 7.5%).

**STATISTICAL ANALYSES.** Data are expressed as mean  $\pm$  SD or as percentages. Confidence interval (CI) width is 95% unless otherwise stated. Basic group comparisons were performed using the Student *t* and chi-square tests. Atherosclerosis prevalence and associated 95% CIs for each territory were calculated after adjusting for age and presented as estimations for an age of 50 years. These were calculated by risk factor count. We also calculated a more detailed table of prevalence, stratified not only by risk factors. Estimates were computed from logistic regression models.


In addition, a logistic model including all of the considered risk factors was used to estimate the independent odds ratios of each risk factor adjusted for age (as a linear variable) for the presence of atherosclerosis in each explored territory. Finally, the association of the presence of plaques in the carotid and femoral arteries with positive coronary calcium was also studied with logistic regression models, adjusted for age (as a linear variable) and traditional risk factors, to estimate potential increases of the area under the receiver-operating characteristic (ROC) curve that may result from adding 1 or both peripheral atherosclerotic measurements to the logistic prediction model and to calculate diagnostic odds ratios. As a sensitivity analysis, we repeated this procedure to estimate the area increases above a logistic prediction on the basis of the calculated ASCVD risk. All statistical processing was performed with R statistical software (21), and ROC curves were calculated with the package pROC (22), using DeLong's methods.

### RESULTS

The studied sample included 1,423 men with a mean age of  $51.0 \pm 3.7$  years. At least 1 atherosclerotic lesion was present in 1,020 participants (72%). Plaques were detected by ultrasound in 65% of participants (34% in the carotid and 54% in the femoral arteries), and 38% had positive coronary calcification (CACS 1 to 299 in 34.5% and  $\geq$ 300 in 3.7%).

ASSOCIATION OF SUBCLINICAL ATHEROSCLEROSIS WITH TRADITIONAL RISK FACTORS. Subclinical atherosclerosis was associated with higher prevalence, higher values, and higher number of known cardiovascular risk factors (Table 1). Figure 1 shows estimates of the expected prevalence and location of subclinical atherosclerosis at 50 years of age, depending on the participants' number of risk factors. Even for participants with no risk factors according to the National Cholesterol Education Program Adult Treatment Panel III thresholds, the estimated prevalence of atherosclerosis in at least 1 territory surpassed 50% and ranged between 21% and 34% for each individual vessel, whereas the calculated prevalence of atherosclerosis in at least 1 territory reached up to 92% for participants with 3 or more risk factors. Detailed age-strata exploration showed that the prevalence of any atherosclerosis rose among participants with no cardiovascular risk factors across the 5-year age strata from 35% (95% CI: 21% to 52%) in the 40- to 44-year age group to 65% (95% CI: 50% to 77%) in the 55- to 59-year age interval (Online Tables 1 and 2).

All traditional risk factors had independent effects on the presence of femoral subclinical atherosclerosis




(Table 2). Current smoking was the independent factor most strongly associated with femoral and carotid plaques, whereas hypertension was the risk factor most strongly associated with the presence of coronary calcium. Only 76 participants had diabetes, and the adjusted association did not show statistical significance for diabetes in the carotid or coronary territories, whereas it was significant for femoral plaques. The accumulation of risk factors had a strong effect on femoral atherosclerosis, which was the territory that drove most of the rise in the association of risk factors with atherosclerotic presence in any territory (Table 2). Figure 2 shows odds ratios of traditional risk factors for subclinical atherosclerosis in each territory. In addition to dependence on modifiable risk factors, the odds of the presence of any atherosclerosis increased by 14% (95% CI: 10% to 18%) per year of age in the studied age range, independently of the existence of other cardiovascular risk factors. This increase was similar for all arteries (carotid: 11%; femoral: 10%; coronary: 13%).

Online Table 3 shows additional data on the ageadjusted prevalence of subclinical atherosclerosis in the different examined locations, according to participants' numbers and types of risk factors.

	n	Any Atherosclerosis (n = 1,020)	Carotid (n = 483)	Femoral (n = 772)	Coronary (n = 544)
CV risk factors					
Dyslipidemia	724	1.53 (1.19-1.96)	1.20 (0.96-1.51)	1.46 (1.17-1.83)	1.24 (0.99-1.55)
Hypertension	550	1.95 (1.49-2.56)	1.41 (1.12-1.78)	1.66 (1.31-2.10)	1.69 (1.34-2.13)
Current smoking	470	3.22 (2.40-4.33)	1.63 (1.28-2.07)	3.88 (3.01-5.00)	1.59 (1.26-2.01)
Diabetes	76	1.55 (0.79-3.02)	1.19 (0.73-1.94)	2.11 (1.20-3.70)	1.29 (0.79-2.10)
Number of CV risk factors					
0	294	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)
1	589	1.85 (1.38-2.48)	1.33 (0.97-1.84)	1.69 (1.26-2.26)	1.95 (1.40-2.70)
2	399	3.66 (2.57-5.20)	1.84 (1.31-2.58)	3.40 (2.47-4.69)	2.69 (1.91-3.79)
3 or 4	141	9.81 (4.92-19.56)	2.69 (1.75-4.15)	10.13 (5.94-17.30)	3.09 (1.99-4.78)

Values are point estimates (95% confidence intervals). Cardiovascular (CV) risk factors are ordered from highest to lowest prevalence in our sample.



The relationship between ASCVD 10-year risk and the extent of subclinical atherosclerosis is shown in **Figure 3**. Among participants at low 10-year risk (<5%), 57% had subclinical atherosclerosis, including 31% with intermediate or generalized disease. Of note, 88% of the participants evaluated as having high 10-year risk ( $\geq$ 7.5%) had subclinical atherosclerosis, with intermediate or generalized disease in 71%.

ASSOCIATION OF CAROTID AND FEMORAL PLAQUES WITH CORONARY CALCIFICATION. Femoral plaques were more strongly associated with CACS  $\geq$ 1 than carotid plaques. Only 53 participants had a CACS  $\geq$ 300, which is the threshold suggested in the 2013 ACC/AHA guidelines for recommendation of statin therapy in the absence of any other indication (4). Of these 53 participants, 50 had femoral plaques, whereas 34 had carotid plaques. Odds ratios of carotid and femoral plaques for detection of CACS  $\geq$ 1 and of CACS  $\geq$ 300 adjusted for cardiovascular risk factors and age are shown in Table 3. The area under the ROC curve for prediction of CACS  $\geq$ 1, considering a model that included dyslipidemia, current smoking, hypertension, diabetes, and age (model 1), increased from 0.665 to 0.689 when the presence of carotid plaques was added into the model (model 2) (p = 0.003) and to 0.706 when the presence of femoral plaques was added (model 3) (p < 0.001). Including both carotid and femoral plaques into the model (model 4) was even better, providing an increase from 0.665 to 0.719 (p < 0.001) (Figure 4). In this extended model, the diagnostic odds ratio for detecting CACS  $\geq$ 1 was 1.80 for carotid plaques and 2.58 for femoral plaques. Even more remarkable were the statistically significant differences between the areas under the ROC curves of the basic model (model 1) and the extended model including both carotid and femoral plaques (model 4) for prediction of CACS  $\geq$ 300: in this case, the area under the ROC curve increased from 0.743 to 0.827 (p < 0.001) (Figure 4). In this model, the diagnostic odds ratio was 8.60 for the femoral arteries and 2.11 for the carotid arteries. Incremental areas under the ROC curves when considering subclinical atherosclerosis are shown in the Central Illustration. Remarkably, using ASCVD risk as the base model, an even greater increase in area was observed after taking plaque detection into account (Online Table 4, Online Figures 1 and 2).

#### DISCUSSION


The most important findings of the present study are that subclinical atherosclerosis in an otherwise healthy middle-aged male cohort is most likely identifiable in femoral arteries, that femoral atherosclerosis shows the strongest association with cardiovascular risk factors, and that femoral plaques show a higher sensitivity than carotid plaques for the presence of calcified coronary disease (CACS ≥1 or  $\geq$ 300) (Central Illustration). These results validate and further expand on those from the recently reported PESA study (Figure 5), which also showed a notably high prevalence of femoral subclinical atherosclerosis in middle-aged subjects, even among those without traditional risk factors (14). In addition, our work also confirms the inaccuracy of the overlap between risk estimated with clinical data and the actual presence and burden of subclinical atherosclerosis (14,23,24).

**EARLY DETECTION OF ATHEROSCLEROSIS TO IMPROVE CARDIOVASCULAR RISK ASSESSMENT.** Early detection and treatment initiation of patients in the process of developing atherosclerosis might be essential for improvement in the prevention of cardiovascular events. Attempts to incorporate carotid intima-media thickness as a marker of risk has yielded mixed data, succeeding in the ARIC study (10), but failing in others (7,8,11). In the meantime, the

evaluation of carotid plaques and coronary calcium scores appeared as valuable markers to increase the predictive capacity of traditional risk prediction models (12,25). Nonetheless, in the 2013 ACC/AHA guideline for CVD risk prediction, there is no mention of carotid ultrasound as a potential additional instrument for risk assessment (5). In the HRP (High Risk Plaque) trial (26), the presence of carotid plaques or positive coronary calcium score in an asymptomatic cohort 55 to 80 years of age predicted the risk of hard cardiovascular events after adjustment for the risk factor set described in the Framingham cohort. Although our study represents a cross-sectional analysis and therefore cannot yet evaluate clinical events, we aimed to complement the predictive models on the basis of traditional risk factors by comparing the presence, location, and extent of subclinical disease across different risk categories. Our results match those of the PESA study (14), showing that most subjects (88% in our study) classified as high risk using a well-established risk scale have subclinical atherosclerosis, with a high proportion having intermediate or generalized disease. More striking is the finding that subclinical atherosclerosis was also present in up to 57% of the AWHS participants considered to be at low risk (58% in the PESA cohort). These results further suggest an association of early atherosclerosis with characteristics not considered in standard risk scales, an aspect that needs further investigation. We propose that patients presenting with subclinical atherosclerosis, despite being classified at low risk, will be more likely to develop clinical events. Follow-up data from AWHS, and from other similar cohorts, will definitely clarify the clinical relevance and the predictive value of early detection of asymptomatic atherosclerosis in otherwise low-risk subjects.

FEMORAL PLAQUES AS A BETTER INDICATOR OF

**CARDIOVASCULAR RISK**. Our data show differences in the association of cardiovascular risk factors with subclinical atherosclerosis in each specific territory. Although the CIs for the odds ratios were wide and partially overlapping, carotid artery atherosclerosis consistently showed a weaker association with traditional cardiovascular risk factors than that observed for femoral atherosclerosis. This might indicate that carotid subclinical atherosclerosis is less useful as a predictive marker than femoral findings. The femoral territory showed a tight association with the independent effect of risk factors, particularly with their confluence in the same person, suggesting that it better reflects the effect of these risk factors and discriminates individual




Presence and extent of subclinical atherosclerosis according to the 10-year risk for atherosclerotic cardiovascular disease (ASCVD) calculated using the Pooled Cohort Equations, classified as low (<5%), moderate (5% to 7.5%), or high ( $\geq$ 7.5%) risk.

**TABLE 3** Diagnostic ORs of Carotid and Femoral Plaques for Detection of Positive ( $\geq$ 1) or High ( $\geq$ 300) CACS, Adjusted for CV Risk Factors and Age, and Changes in Areas Under the Curve for Prediction

For Detection of:	Diagnostic OR	Area Under the Curve	p Value Carotid vs. Femoral	p Value vs. Base	p Value vs. Full
CACS $\geq$ 1 (n = 544)					
Model 1		0.665 (0.637-0.693)		(Ref.)	< 0.001
(basic model)	-				
Model 2		0.689 (0.661-0.716)	(Ref.)	0.003	<0.001
(+ carotid plaques)	2.04				
Model 3		0.706 (0.679-0.733)	0.137	< 0.001	0.012
(+ femoral plaques)	2.80				
Model 4		0.719 (0.692-0.745)		< 0.001	(Ref.)
(+ carotid plaques	1.80				
+ femoral plaques)	2.58				
$CACS \geq \!\! 300 \text{ (n} = \! 53)$					
Model 1		0.743 (0.673-0.813)		(Ref.)	<0.001
(basic model)	-				
Model 2		0.778 (0.712-0.845)	(Ref.)	0.046	0.003
(+ carotid plaques)	2.63				
Model 3		0.810 (0.760-0.859)	0.142	0.001	0.088
(+ femoral plaques)	9.91				
Model 4		0.827 (0.778-0.877)		< 0.001	(Ref.)
(+ carotid plaques	2.11				
+ femoral plaques)	8.60				

Area under the curve values are point estimates (95% confidence intervals). The basic model includes dyslipidemia, current smoking, hypertension, diabetes, and age. The 3 right columns show the statistical significance of the differences between the models: the first of these columns evaluates the area of the model that adds femoral plaques using the model that adds carotid plaques as a reference; the second column uses the base model as a reference; and the third column uses the full model as a reference.


CACS = coronary artery calcium score; CV = cardiovascular; OR = odds ratio; Ref. = reference.



Receiver-operating characteristic curves for positive  $(\geq 1)$  (A) or high  $(\geq 300)$  (B) coronary artery calcium score (CACS), comparing models on the basis of only traditional cardio-vascular risk factors (CVRF) (dyslipidemia, current smoking, hypertension, diabetes, and age) with models that additionally consider the presence of plaques in the carotid and/or femoral arteries. AUC = area under the receiver-operating characteristic curve.

susceptibilities to cardiovascular disease. However, the disproportionately high association of current smoking with femoral subclinical atherosclerosis might indicate that detection of femoral plaques is a less specific marker in smokers than in nonsmokers. Tobacco consumption is highly associated with lower extremity peripheral arterial disease (27), increasing the risk of this disease by 2- to 6-fold and the risk of intermittent claudication by 3- to 10-fold (28-30). Subclinical disease reproduces this known higher clinical effect of tobacco on the femoral arteries than on other territories: our data show that the prevalence of femoral plaques is much higher among current smokers. Nevertheless, in sensitivity analyses, the overall predictive capacity of femoral subclinical atherosclerosis was not affected by adjusting the models for former smoker status, and current smoking was not an effect modifier of the association of femoral plaques with positive coronary calcium (data not shown). Our conclusions can thus be applied to smokers and nonsmokers, but future studies should explore how these associations might change among smokers and how to control this potential problem.

FEMORAL PLAQUES FOR PREDICTION OF CORONARY CALCIFICATION. In autopsy studies, the presence of femoral plaques was much more strongly associated with coronary plaques and coronary deaths (31) than plaques in the common carotid arteries (32). As a clinical reflection of these anatomic studies, patients with symptomatic lower extremity peripheral artery disease are characterized by extensive and concomitant atherosclerosis in other territories and have a high risk of cardiac events (27,33), a risk even higher than that of ischemic limb events (33). In a study of CVD in older patients, 68% with peripheral artery disease had coexistent coronary disease (34). In the CAPRIE (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events) trial, >50% of patients who enrolled in the study because of peripheral artery disease had concomitant coronary or cerebrovascular disease (35), and the presence of symptomatic peripheral artery disease was associated with an approximately 4-fold excess of coronary events (36). One could argue that early, asymptomatic phases of peripheral artery disease might not show similar associations. However, men included in the ARIC study with an ankle-brachial index <0.90, an indicator of lower extremity peripheral artery disease, were twice as likely to have prevalent coronary heart disease (37). Together, these findings demonstrate that both early and late stages of lower-extremity arteriosclerotic disease are highly indicative of




Shown is the improvement in the prediction of coronary calcification conferred by adding the presence of atherosclerosis in different territories to classical risk factors. Areas under the receiver-operating characteristic (ROC) curve for prediction of positive ( $\geq$ 1) or high ( $\geq$ 300) coronary artery calcium score (CACS) are shown on the basis of age and cardiovascular risk factors alone and then taking into account the presence of carotid and/or femoral plaques.

generalized atherosclerosis and support our data indicating that early detection of femoral plaques has strong potential as a marker for coronary disease risk prediction. In fact, our analysis demonstrates that diagnostic accuracy for prediction of coronary calcification in asymptomatic subjects (used as the best available noninvasive surrogate for coronary atherosclerosis), using either individual risk factors or the Pooled Cohort Equations for risk estimation, can be significantly improved by considering the presence of carotid and/or femoral plaques, especially the presence of femoral plaques (Central Illustration).

**STUDY LIMITATIONS AND STRENGTHS**. Our study has several limitations. First, this is a cross-sectional analysis, which limits the temporal interpretation of predictive measurements. Second, because a positive coronary calcium score is only an indirect surrogate marker of clinical atherosclerotic disease, our data do

not directly demonstrate a predictive clinical value for femoral plaques, and we cannot deduce that femoral atherosclerosis will be a better predictor of coronary events than carotid plaques. However, coronary calcium does reflect pathological alteration of the coronary arteries, and our findings therefore demonstrate an association of femoral plaques with situations in which the coronary territory is affected by atherosclerosis to a certain extent. Third, our sample is composed of middle-aged men, which limits generalizability of the findings, especially to women. In addition, extrapolation of our results to non-Mediterranean populations might also be imprecise, and for this reason, our results should be validated in other cohorts. Also, the relative influence of each risk factor within an individual territory must be interpreted with caution for 2 reasons: these comparisons did not form part of the design of this study, and the CIs were wide. Consequently,



conclusions about which risk factor might be the most influential are uncertain, with the exception of smoking, which had a strong signal.

Strengths of our study include the collection of clinical and imaging data according to strict protocols and the defined age range in this male population. Indeed, the homogeneous age profile and the restriction to men helped to control for the most important confounding factors. Potential confounders have been addressed in the regression models, and the prospective design of AWHS and other ongoing studies will eventually provide comprehensive information about the prospective predictive value of the measurements studied here.

## CONCLUSIONS

The data presented here show that femoral atherosclerotic plaques are the most frequent subclinical atherosclerotic alterations in middle-aged men that are accessible by noninvasive diagnostic imaging. Compared with plaques in the carotid arteries, femoral plaques show stronger associations with traditional cardiovascular risk factors and with a positive coronary calcium score. Screening for femoral plaques, alone or together with carotid plaques, adds predictive value to traditional cardiovascular risk factors for the detection of coronary artery calcification. Assessment of femoral plaques with vascular ultrasound is an appealing strategy for predicting future coronary events and a potential tool for improving patient stratification to achieve more efficient primary prevention.

ACKNOWLEDGMENTS The authors thank the study participants, doctors, and health care professionals at the General Motors factory. The authors also thank the AWHS technical staff: Angeles Bamala, Raquel Langarita, Marta Ledesma, Belén Moreno, Elisabeth Penón, Natalia Sanchez, Zoraida Soriano, and Rosa Villa; Dr. Juan J. Soriano, who supervised CT studies; and Simon Bartlett for text revision.

**REPRINT REQUESTS AND CORRESPONDENCE**: Dr. Valentin Fuster, Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, New York 10029. E-mail: valentin.fuster@mountsinai.org.

#### PERSPECTIVES

**COMPETENCY IN MEDICAL KNOWLEDGE:** The most frequently affected site at early asymptomatic stages of atherosclerosis is the femoral territory. Compared with plaques in the carotid arteries, femoral plaques show stronger associations with traditional cardiovascular risk factors and with the presence of coronary calcification.

#### COMPETENCY IN PATIENT CARE AND PROCE-

**DURAL SKILLS:** Subclinical atherosclerosis is present in up to 57% of the AWHS participants who are considered to be at low risk when applying risk scales on the basis of traditional risk factors. This result further suggests an

association of early atherosclerosis with characteristics not considered in standard risk scales, an aspect that needs further investigation.

**TRANSLATIONAL OUTLOOK:** Follow-up data from AWHS and from other similar cohorts will definitely clarify the clinical relevance and the predictive value of early detection of asymptomatic atherosclerosis in otherwise low-risk patients. Screening for femoral plaques, rather than carotid plaques, may be an appealing strategy for improving cardiovascular risk scales and predicting coronary disease.

#### REFERENCES

**1.** Mendis S, Puska P, Norrving B, editors. Global Atlas on Cardiovascular Disease Prevention and Control. Geneva, Switzerland: World Health Organization, 2011.

2. Lammintausta A, Airaksinen JK, Immonen-Räihä P, et al., for the FINAMI Study Group. Prognosis of acute coronary events is worse in patients living alone: the FINAMI myocardial infarction register. Eur J Prev Cardiol 2014;21: 989–96.

**3.** Koopman C, Bots ML, van Oeffelen AAM, et al. Population trends and inequalities in incidence and short-term outcome of acute myocardial infarction between 1998 and 2007. Int J Cardiol 2013;168: 993-8.

**4.** Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889–934.

**5.** Goff DC Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014:63:2935–59.

**6.** Polak JF, Pencina MJ, Pencina KM, et al. Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med 2011;365:213-21.

**7.** Den Ruijter HM, Peters SAE, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA 2012;308:796-803.

**8.** Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358: 1336-45.

**9.** Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007;115:459-67.

**10.** Nambi V, Chambless L, Folsom AR, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol 2010;55: 1600-7.

**11.** Van den Oord SCH, Sijbrands EJG, ten Kate GL, et al. Carotid intima-media thickness for cardio-vascular risk assessment: systematic review and meta-analysis. Atherosclerosis 2013;228:1-11.

**12.** Inaba Y, Chen JA, Bergmann SR. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis. Atherosclerosis 2012;220:128-33.

**13.** Pasterkamp G, Schoneveld AH, Hillen B, et al. Is plaque formation in the common carotid artery representative for plaque formation and luminal stenosis in other atherosclerotic peripheral arteries? A post mortem study. Atherosclerosis 1998;137:205-10.

**14.** Fernández-Friera L, Peñalvo JL, Fernández-Ortiz A, et al. Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle-aged cohort: the PESA (Progression of Early Subclinical Atherosclerosis) Study. Circulation 2015;131:2104-13.

**15.** Casasnovas JA, Alcaide V, Civeira F, et al. Aragon Workers' Health Study-design and cohort description. BMC Cardiovasc Disord 2012;12:45.

**16.** Muntendam P, McCall C, Sanz J, et al., for the High-Risk Plaque Initiative. The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease—study design and objectives. Am Heart J 2010;160:49–57.e1.

**17.** Junyent M, Gilabert R, Zambón D, et al. Femoral atherosclerosis in heterozygous familial hypercholesterolemia: influence of the genetic defect. Arterioscler Thromb Vasc Biol 2008;28: 580-6.

**18.** Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827-32.

**19.** Pearson TA, Palaniappan LP, Artinian NT, et al., for the American Heart Association Council on Epidemiology and Prevention. American Heart Association guide for improving cardiovascular health at the community level, 2013 update: a scientific statement for public health practitioners, healthcare providers, and health policy makers. Circulation 2013;127:1730-53.

**20.** Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002;106:3143-421.

**21.** R Core Team. R: A Language and Environment for Statistical Computing. 2015. Vienna, Austria. Available at: http://www.R-project.org/. Accessed January 8, 2016.

**22.** Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12: 77.

**23.** Postley JE, Perez A, Wong ND, et al. Prevalence and distribution of sub-clinical atherosclerosis by screening vascular ultrasound in low and intermediate risk adults: the New York Physicians Study. J Am Soc Echocardiogr 2009;22:1145-51.

**24.** Postley JE, Luo Y, Wong ND, et al. Identification by ultrasound evaluation of the carotid and femoral arteries of high-risk subjects missed by three validated cardiovascular disease risk algorithms. Am J Cardiol 2015;116:1617-23. **25.** Youssef G, Kalia N, Darabian S, et al. Coronary calcium: new insights, recent data, and clinical role. Curr Cardiol Rep 2013;15:325.

**26.** Sillesen H, Muntendam P, Adourian A, et al. Carotid plaque burden as a measure of subclinical atherosclerosis: comparison with other tests for subclinical arterial disease in the High Risk Plaque Biolmage study. J Am Coll Cardiol Img 2012;5:681-9.

**27.** Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011;58:2020-45.

**28.** Price JF, Mowbray PI, Lee AJ, et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J 1999;20:344–53.

**29.** Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 1985;33:13–8.

**30.** Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. Circulation 1990;82: 1925-31.

**31.** Dalager S, Falk E, Kristensen IB, et al. Plaque in superficial femoral arteries indicates generalized atherosclerosis and vulnerability to coronary death: an autopsy study. J Vasc Surg 2008;47: 296-302.

**32.** Molnár S, Kerényi L, Ritter MA, et al. Correlations between the atherosclerotic changes of femoral, carotid and coronary arteries: a post mortem study. J Neurol Sci 2009;287:241-5.

**33.** Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326:381-6.

**34.** Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1999;47:1255-6.

**35.** CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.

**36.** Criqui MH, Denenberg JO, Langer RD, et al. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 1997;2:221-6.

**37.** Zheng ZJ, Sharrett AR, Chambless LE, et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk In Communities (ARIC) Study. Atherosclerosis 1997;131:115-25.

**KEY WORDS** cohort, computed tomography, risk assessment, ultrasonography

**APPENDIX** For supplemental methods and figures and tables, please see the online version of this article.